Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to evaluate the real-world effectiveness of benralizumab on asthma exacerbations and OCS use in patients with severe eosinophilic asthma with available blood eosinophil lab measures and those who switched from omalizumab or mepolizumab

Next Previous
Trial Profile

A study to evaluate the real-world effectiveness of benralizumab on asthma exacerbations and OCS use in patients with severe eosinophilic asthma with available blood eosinophil lab measures and those who switched from omalizumab or mepolizumab

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Benralizumab (Primary) ; Corticosteroid
  • Indications Asthma; Eosinophilia
  • Focus Therapeutic Use
  • Acronyms ZEPHYR 2

Most Recent Events

  • 14 Nov 2022 Results assessing real-world effectiveness of benralizumab on asthma exacerbations and NP-related outpatient and oral corticosteroid (OCS) use in severe eosinophilic asthma patients comorbid nasal polyps, presented at the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology.
  • 19 Oct 2022 Results assessing long-term (for up to 24 months of follow-up) effectiveness of benralizumab in patients with severe eosinophilic asthma, presented at the CHEST Annual Meeting 2022 by Annual Meeting of the American College of Chest Physicians.
  • 28 Feb 2022 Results (n=1292) presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top